# Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)

> **NCT05422781** · PHASE1 · COMPLETED · sponsor: **Immunomic Therapeutics, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Merkel Cell Carcinoma

## Interventions

- **DRUG:** ITI-3000

## Key facts

- **NCT ID:** NCT05422781
- **Lead sponsor:** Immunomic Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-13
- **Primary completion:** 2023-06-27
- **Final completion:** 2023-06-27
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05422781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05422781, "Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05422781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*